New drug cocktail targets Hard-to-Treat colorectal cancer mutation
NCT ID NCT06959589
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drug combinations for people with advanced colorectal cancer that has a specific genetic change called KRAS G12C. In one group, patients who haven't had treatment yet will receive the drugs IBI351 and cetuximab β plus chemotherapy (FOLFIRI). In another group, patients whose cancer got worse after first treatment will get just IBI351 and cetuximab β. The goal is to see if these combinations shrink tumors better than past treatments. About 50 adults aged 18-75 will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBI351 and cetuximab β (with or without FOLFIRI chemotherapy)
What this could lead to
If successful, this could offer a new targeted treatment option for people with a specific genetic mutation (KRAS G12C) in advanced colorectal cancer, potentially improving tumor shrinkage rates.
What could go wrong
This is a small, early-phase (Phase II) study with only 50 participants, so results may not apply broadly. The combination may cause side effects, and the expected improvement in remission rates is not guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310000, China